

JAN 21 2000

510(k) Summary

Device: Citation TMZF HA Stem

The Citation TMZF HA Stems are anatomic stems in a variety of lengths and distal diameters. The larger diameter stems have a rotated distal slot that contains distal flutes or grooves.

This stem is intended for the reconstruction of the head and neck of the femoral joint. The device is intended for primary reconstruction of the proximal femur or revision of a previous total hip arthroplasty. The stems can be used with any currently available Howmedica Osteonics acetabular components and V40 Femoral Heads that can be mated with a 5° 40' BG taper.

The Citation TMZF HA Stems will be fabricated from TMZF Alloy. The stems are coated with a CP Titanium plasma spray coating and Pure-Fix™ HA.

The substantial equivalence of the Citation TMZF HA Stems is based upon equivalence in intended use, materials, design, and operational principles to Meridian® Titanium Femoral Stem (K972228); the Howmedica® Asymmetric Stem Femoral Component (K955871); and the Osteonics® Omnifit® AD-HA Hip Stem Series (K941366).

Testing indicates that the addition of the HA coating over plasma spray has no effect on the stem fatigue strength.

For information contact: Jennifer A. Daudelin
Rutherford Regulatory Affairs
Howmedica Osteonics Corp.
359 Veterans Boulevard
Rutherford, NJ 07070
Phone: (201) 507-7283
Fax: (201) 507-6870



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JAN 21 2000

Ms. Jennifer A. Daudelin
Regulatory Affairs
Stryker Howmedica Osteonics
359 Veterans Boulevard
Rutherford, New Jersey 07070

Re: K993768
Trade Name: Citation TMZF HA Stem
Regulatory Class: II
Product Code: MEH
Dated: October 29, 1999
Received: November 8, 1999

Dear Ms. Daudelin:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 - Ms. Jennifer A. Daudelin

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



James E. Dillard III
Acting Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

